Tagrisso (osimertinib), AstraZeneca’s lung cancer treatment, has become the first product to be approved by the UK medicines regulator under Project Orbis, the US-led scheme that enables international regulators to simultaneously review new cancer drugs and approve them faster.
UK Pips EU To The Post With ‘Project Orbis’ Approval For Tagrisso
EU Early-Use Approval For AstraZeneca’s NSCLC Drug Imminent
The UK drug regulator, the MHRA, has approved its first product under Project Orbis, the US-led international regulatory collaboration scheme it joined four months ago to speed up access to promising cancer medicines.
More from United Kingdom
• By
England’s health technology assessment institute, NICE, is looking to “reimagine” its evaluation process with the help of AI, rather than just using this technology to speed up its existing processes.
• By
Pharmaceutical companies are being encouraged to reach out to NICE in relation to its HTA Innovation Lab, which provides a sandbox environment in which the health technology assessment body can test new methods of evaluating “innovative and disruptive” therapies.
• By
Health technology assessment body NICE said it has taken on feedback about the implications of allowing higher cost-effectiveness thresholds for some medicines after senior health economists offered diverging views on its methods.
• By
Cell and gene therapy manufacturers must consider the practicalities of their product within the context of a health care system before it comes onto the market to be successful, experts from Novartis, AstraZeneca and England’s National Health Service say.